267 related articles for article (PubMed ID: 24317334)
1. mRECIST criteria and contrast-enhanced US for the assessment of the response of hepatocellular carcinoma to transarterial chemoembolization.
Moschouris H; Malagari K; Papadaki MG; Kornezos I; Stamatiou K; Anagnostopoulos A; Chatzimichael K; Kelekis N
Diagn Interv Radiol; 2014; 20(2):136-42. PubMed ID: 24317334
[TBL] [Abstract][Full Text] [Related]
2. Transarterial Chemoembolization of HCC with Radiopaque Microspheres: Evaluation with Computed Tomography and the Complementary Role of Contrast-Enhanced Ultrasonography.
Moschouris H; Malagari K; Dimakis A; Kiakidis T; Anagnostopoulou A
Cardiovasc Intervent Radiol; 2020 Jul; 43(7):1075-1083. PubMed ID: 32394087
[TBL] [Abstract][Full Text] [Related]
3. Imaging of intrahepatic progression of hepatocellular carcinoma post transarterial chemoembolization. A long-term, prospective evaluation of contrast-enhanced ultrasonography (CEUS).
Moschouris H; Kalokairinou-Motogna M; Vrakas S; Papadatou A; Karagiannis E; Kiltenis M; Kladis-Kalentzis K; Marmaridou K; Papadogeorgopoulos N; Malagari K
Med Ultrason; 2017 Apr; 19(2):134-142. PubMed ID: 28440346
[TBL] [Abstract][Full Text] [Related]
4. Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?
Zhao Y; Duran R; Bai W; Sahu S; Wang W; Kabus S; Lin M; Han G; Geschwind JF
Cardiovasc Intervent Radiol; 2018 Mar; 41(3):433-442. PubMed ID: 29086058
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Texture Analysis Parameter for Response Prediction in Patients with Hepatocellular Carcinoma Undergoing Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) Using Biphasic Contrast-enhanced CT Image Data: Correlation with Liver Perfusion CT.
Kloth C; Thaiss WM; Kärgel R; Grimmer R; Fritz J; Ioanoviciu SD; Ketelsen D; Nikolaou K; Horger M
Acad Radiol; 2017 Nov; 24(11):1352-1363. PubMed ID: 28652049
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors of contrast-enhanced ultrasonography for the response to transarterial chemoembolization in hepatocellular carcinoma.
Park KH; Kwon SH; Lee YS; Jeong SW; Jang JY; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Kim YJ
Clin Mol Hepatol; 2015 Jun; 21(2):158-64. PubMed ID: 26157753
[TBL] [Abstract][Full Text] [Related]
7. Comparison of contrast-enhanced ultrasound and contrast-enhanced computed tomography in evaluating the treatment response to transcatheter arterial chemoembolization of hepatocellular carcinoma using modified RECIST.
Liu M; Lin MX; Lu MD; Xu ZF; Zheng KG; Wang W; Kuang M; Zhuang WQ; Xie XY
Eur Radiol; 2015 Aug; 25(8):2502-11. PubMed ID: 25702094
[TBL] [Abstract][Full Text] [Related]
8. Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria.
Shim JH; Han S; Shin YM; Yu E; Park W; Kim KM; Lim YS; Lee HC
J Vasc Interv Radiol; 2013 Mar; 24(3):316-25. PubMed ID: 23312990
[TBL] [Abstract][Full Text] [Related]
9. Intraarterial contrast-enhanced ultrasound to predict the short-term tumour response of hepatocellular carcinoma to Transarterial chemoembolization with Lipiodol.
Bo J; Peng H; LianHua Z; Xiang F; YuKun L
BMC Cancer; 2021 Nov; 21(1):1171. PubMed ID: 34727882
[TBL] [Abstract][Full Text] [Related]
10. Transarterial Chemoembolization Using 100-μm Drug-Eluting Microspheres in Patients with Hepatocellular Carcinoma: A Prospective Study and Midterm Follow-up.
Ou HY; Wu YN; Yu CY; Chen CL; Hsu HW; Weng CC; Leung-Chit Tsang L; Huang TL; Tong YS; Lim WX; Cheng YF
J Vasc Interv Radiol; 2020 Nov; 31(11):1784-1791. PubMed ID: 33023805
[TBL] [Abstract][Full Text] [Related]
11. Contrast-Enhanced Ultrasonography Versus Contrast-Enhanced Computed Tomography for Assessment of Residual Tumor From Hepatocellular Carcinoma Treated With Transarterial Chemoembolization: A Meta-analysis.
Zhong J; Su Z; Zhang Y; Zhang H; Lin P; Tang X; Zheng R
J Ultrasound Med; 2018 Aug; 37(8):1881-1890. PubMed ID: 29380404
[TBL] [Abstract][Full Text] [Related]
12. Reproducibility of mRECIST in Measurement and Response Assessment for Hepatocellular Carcinoma Treated by Transarterial Chemoembolization.
Choi MH; Park GE; Oh SN; Park MY; Rha SE; Lee YJ; Jung SE; Choi JI
Acad Radiol; 2018 Nov; 25(11):1363-1373. PubMed ID: 29555570
[TBL] [Abstract][Full Text] [Related]
13. Irreversible electroporation of hepatocellular carcinoma: preliminary report on the diagnostic accuracy of magnetic resonance, computer tomography, and contrast-enhanced ultrasound in evaluation of the ablated area.
Granata V; de Lutio di Castelguidone E; Fusco R; Catalano O; Piccirillo M; Palaia R; Izzo F; Gallipoli AD; Petrillo A
Radiol Med; 2016 Feb; 121(2):122-31. PubMed ID: 26345332
[TBL] [Abstract][Full Text] [Related]
14. Comparison of volume perfusion computed tomography and contrast-enhanced ultrasound for assessment of therapeutic effect of transarterial chemoembolization in patients with hepatocellular carcinoma: a preliminary report.
Kaufmann S; Schulze M; Spira D; Horger M
Acta Radiol; 2016 Jan; 57(1):8-12. PubMed ID: 25585848
[TBL] [Abstract][Full Text] [Related]
15. The usefulness of contrast-enhanced ultrasonography in the early detection of hepatocellular carcinoma viability after transarterial chemoembolization: pilot study.
Cho YZ; Park SY; Choi EH; Baik SK; Kwon SO; Kim YJ; Cha SH; Kim MY
Clin Mol Hepatol; 2015 Jun; 21(2):165-74. PubMed ID: 26157754
[TBL] [Abstract][Full Text] [Related]
16. Comparison of α-Fetoprotein Criteria and Modified Response Evaluation Criteria in Solid Tumors for the Prediction of Overall Survival of Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization.
Zhang YQ; Jiang LJ; Wen J; Liu DM; Huang GH; Wang Y; Fan WZ; Li JP
J Vasc Interv Radiol; 2018 Dec; 29(12):1654-1661. PubMed ID: 30396842
[TBL] [Abstract][Full Text] [Related]
17. Contrast-enhanced ultrasound as a predictor of treatment efficacy within 2 weeks after transarterial chemoembolization of hepatocellular carcinoma.
Kono Y; Lucidarme O; Choi SH; Rose SC; Hassanein TI; Alpert E; Mattrey RF
J Vasc Interv Radiol; 2007 Jan; 18(1 Pt 1):57-65. PubMed ID: 17296705
[TBL] [Abstract][Full Text] [Related]
18. Correlation between SACE (Subjective Angiographic Chemoembolization Endpoint) score and tumor response and its impact on survival after DEB-TACE in patients with hepatocellular carcinoma.
Habbel VSA; Zeile M; Stavrou GA; Wacker F; Brüning R; Oldhafer KJ; Rodt T
Abdom Radiol (NY); 2019 Oct; 44(10):3463-3479. PubMed ID: 31332502
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma.
Hyun D; Shin SW; Cho SK; Park KB; Park HS; Choo SW; Do YS; Choo IW; Shin JW; Lim SJ
Acta Radiol; 2015 Dec; 56(12):1437-45. PubMed ID: 25480473
[TBL] [Abstract][Full Text] [Related]
20. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).
Prajapati HJ; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
Ann Oncol; 2013 Apr; 24(4):965-73. PubMed ID: 23223331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
